| Name | Title | Contact Details |
|---|
Healthpoint Biotherapeutics is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Early Bird is the first and only FDA-approved bleed detection system for peri and post-procedural monitoring of endovascular procedures.
Cellular Dynamics International, Inc. develops and manufactures human cells in the United States of America, Europe, Japan, and internationally. The company’s proprietary iCell Operating System comprises human cells in multiple cell types (iCell products), human induced pluripotent stem cells (iPSCs), and custom iPSCs and iCell products (MyCell products). It offers iCell Cardiomyocytes, which are purified human heart cells that beat in a dish and behave just like the heart cells found in the human body for in vitro drug discovery, toxicity testing, and chemical safety, as well as in vivo cellular therapeutics research and development, and stem cell banking; and iCell Neurons that are purified human neurons typical of the forebrain for pre-clinical drug discovery, neurotoxicity testing, and disease modeling for Alzheimer’s diseases, Parkinson’s diseases, Huntington’s diseases, and others. The company also provides iCell Endothelial cells, which are interior surface blood vessel cells for use in vascular biology research, such as angiogenesis, atherosclerosis, inflammation, and other life science research; and iCell Hepatocytes that are human liver cells for pre-clinical drug discovery, hepatotoxicity testing, disease modeling, and other life science research. In addition, it offers MyCell products for making iPSCs for stem cell banking, cell modeling of specific ethnic or disease populations, and genetic engineering for in vitro research; and media and reprogramming kits for making iPSCs for limited research use. The company serves biopharmaceutical companies, government research institutions, academic and nonprofit research institutions, contract research organizations, and stem cell banks. Cellular Dynamics International, Inc. was founded in 2004 and is headquartered in Madison, Wisconsin.
Norbrook® is a true innovator and dedicated to novel research and revolutionary processes and products. Lord Ballyedmond, Founder, Chairman and CEO of the Norbrook Group began his career in the pharmaceutical industry in the USA in the 1960s and now controls the largest privately owned pharmaceutical company in the world. The company is very active in both medical and veterinary products. Research and Development is the key to Norbrook`s success with the R&D Department central to the company`s structure. It is responsible for new product development, technical support and meeting regulatory and licensing protocols. Norbrook invests more than 10% of its turnover annually in research and development of new products. The company is at the forefront of formulation technology and has developed many new chemical routes for the synthesis of active materials. Norbrook has formulated and registered more than 800 products in 120 countries. The on-going success of the company is conditional on the expertise, knowledge and innovation of the staff employed. Norbrook prides itself on attracting the highest calibre of individual to the company and boasts a multi-national workforce committed to constantly pushing the boundaries and challenging technologies to ensure that Norbrook remains the leading force in pharmaceuticals that it is today.
University Compounding Pharmacy is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.